ID: ALA24291

Max Phase: Preclinical

Molecular Formula: C23H34N2O3

Molecular Weight: 386.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@]12CCC(=O)C=C1NCC1C2CC[C@@]2(C)C1CC[C@@H]2C(=O)N1CCOCC1

Standard InChI:  InChI=1S/C23H34N2O3/c1-22-8-6-18-16(14-24-20-13-15(26)5-7-23(18,20)2)17(22)3-4-19(22)21(27)25-9-11-28-12-10-25/h13,16-19,24H,3-12,14H2,1-2H3/t16?,17?,18?,19-,22+,23-/m1/s1

Standard InChI Key:  ACOCIZXLRWIONJ-PAJIOFOTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 386.54

Molecular Weight (Monoisotopic): 386.2569

AlogP: 2.76

#Rotatable Bonds: 1

Polar Surface Area: 58.64

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.49

CX LogP: 1.75

CX LogD: 1.75

Aromatic Rings: 0

Heavy Atoms: 28

QED Weighted: 0.75

Np Likeness Score: 0.88

References

1. Kenny B, Ballard S, Blagg J, Fox D..  (1997)  Pharmacological options in the treatment of benign prostatic hyperplasia.,  40  (9): [PMID:9135028] [10.1021/jm960697s]

2. Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Cribbs CM, Wheeler TN, Ray JA, Andrews RC..  (1994)  6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.,  37  (15): [PMID:8057283] [10.1021/jm00041a014]

3. Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Batchelor KW, Bramson HN, Stuart JD, Schweiker SL..  (1993)  6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.,  36  (26): [PMID:8277514] [10.1021/jm00078a022]

Source

Source(1):

• Scientific Literature